Reduction of Anticholinergic Medications Among Persons With Schizophrenia or Other Psychiatric Disorders

NARecruitingINTERVENTIONAL
Enrollment

111

Participants

Timeline

Start Date

July 16, 2025

Primary Completion Date

May 31, 2026

Study Completion Date

May 31, 2026

Conditions
Schizophenia DisorderSchizoaffective DisorderBipolar DisorderPsychiatric Disorders
Interventions
OTHER

Reduction of anticholinergic medication

Shared decision making between the patient and prescriber will determine the timing and speed of reduction over a period of 12 to 16 weeks. Some patients will be discontinued from these anticholinergic medications (benztropine/trihexyphenidyl), others will be tapered from their original dosage but not completely discontinued, and some patients may not be able to taper the anticholinergic medications at all.

Trial Locations (4)

15213

NOT_YET_RECRUITING

Comprehensive Recovery Services (Pittsburgh) of Western Psychiatric Hospital, Ambulatory Clinics and Residential Programs - UPMC, Pittsburgh, PA, Pittsburgh

16508

RECRUITING

UPMC Western Behavioral Health at Safe Harbor, Erie

16601

NOT_YET_RECRUITING

Western Behavioral Health of the Alleghenies, Altoona

NOT_YET_RECRUITING

Western Behavioral Health Mon Yough, McKeesport

All Listed Sponsors
collaborator

National Center for Advancing Translational Sciences (NCATS)

NIH

collaborator

University of Pittsburgh Medical Center

OTHER

lead

University of Pittsburgh

OTHER

NCT07043803 - Reduction of Anticholinergic Medications Among Persons With Schizophrenia or Other Psychiatric Disorders | Biotech Hunter | Biotech Hunter